Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

‘All Airlines Are Poised to Bounce’: Citi Makes the Case for Buying These 2 Airline Stocks Now

View original at finance.yahoo.com
‘All Airlines Are Poised to Bounce’: Citi Makes the Case for Buying These 2 Airline Stocks Now The airline industry struggled over the past year, with multiple headwinds weighing on demand…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Legacy low-cost carriers will be relative underperformers through the cycle

    80% confidence
  • Risks of structural impairment at American Airlines are overstated; if AAL demonstrates company-specific momentum, stock offers most significant upside potential among supermajors

    80% confidence
  • Alaska Air is most supermajor-like of non-supermajor carriers and management strategy leans toward developing supermajor strengths

    80% confidence
  • Alaska Air rated Buy with $61 price target representing 23% upside potential

    80% confidence
  • Supermajors will be biggest beneficiaries through the airline industry cycle with most favorable risk/reward

    80% confidence
  • Alaska Air's Accelerate target of >$10/share in EPS in 2027 is still possible despite consensus backing away

    80% confidence
  • American Airlines rated Buy with $19 price target representing 28% upside potential

    80% confidence
  • Recent pullback in Alaska Air shares creates unusual opportunity to build long-term position at near tactical lows

    80% confidence
  • All airlines are poised to bounce with positive setup for elongated mid-cycle beginning in 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
‘All Airlines Are Poised to Bounce’: Citi Makes the Case for Buying These 2 Airline Stocks Now — Source | Via News | Via News